key: cord-0516707-1c313pxo
authors: Lee, Kwangmin; Jo, Seongil; Lee, Jaeyong
title: Seroprevalence of SARS-CoV-2 antibodies in South Korea
date: 2021-01-28
journal: nan
DOI: nan
sha: d0bb9206d7014f92087088f57c40753a62c8af56
doc_id: 516707
cord_uid: 1c313pxo

In $2020$, Korea Disease Control and Prevention Agency reported three rounds of surveys on seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in South Korea. We analyze the seroprevalence surveys using a Bayesian method with an informative prior distribution on the seroprevalence parameter, and the sensitivity and specificity of the diagnostic test. We construct the informative prior using the posterior distribution obtained from the clinical evaluation data based on the plaque reduction neutralization test. The constraint of the seroprevalence parameter induced from the known confirmed coronavirus 2019 cases can be imposed naturally in the proposed Bayesian model. We also prove that the confidence interval of the seroprevalence parameter based on the Rao's test can be the empty set, while the Bayesian method renders a reasonable interval estimator. As of the $30$th of October $2020$, the $95%$ credible interval of the estimated SARS-CoV-2 positive population does not exceed $307,448$, approximately $0.6%$ of the Korean population.

that the confidence interval of the seroprevalence parameter based on the Rao's test can be the empty set, while the Bayesian method renders a reasonable interval estimator. As of the 30th of October 2020, the 95% credible interval of the estimated SARS-CoV-2 positive population does not exceed 307, 448, approximately 0.6% of the Korean population.

In December 2019, the Chinese government reported a cluster of pneumonia patients of unknown cause in Wuhan, China. It was found that an unknown betacoronavirus causes the disease (Zhu et al.; . The Coronaviridae Study Group (CSG) of the International Committee on Taxonomy of Viruses has named the virus as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), due to the similarity to SARS-CoV (Gorbalenya et al.; . The World Health Organization (WHO) also has named the disease caused by SARS-CoV-2 as COVID-19, short for coronavirus disease 2019 (The World Health Organization; 2020a). As of January 10, 2021, over 90, 000, 000 people in the world are confirmed positive for COVID-19, and there are over 68, 000 confirmed cases in South

Korea.

Most statistical approaches use the number of confirmed cases to assess the spread of infectious diseases in a population. However, the number of confirmed cases does not include those that are infected but not detected. A seroprevalence survey can be an alternative in this case. The seroprevalence is the number of people with antibodies to the virus in a population. The WHO (2020b) proposes to analyze seroprevalence surveys for the inference on the spread of a novel coronavirus. Seroprevalence surveys have been conducted in many countries, and the results are collected in Serotracker, a global seroprevalence dashboard (Arora et al.; . According to the recent update on December 12, 2020, Serotracker provides the survey results of 56 countries based on 491 studies.

The seroprevalence survey data can be analyzed under either the assumption that the diagnostic tests used in the survey are 100% accurate or the assumption that the tests are not 100% accurate. We will term these assumptions as the accuracy assumption and the inaccuracy assumption, respectively. Under the accuracy assumption, Song et al. (2020) and Noh et al. (2020) analyzed outpatient data sets in southwestern Seoul and Daegu, respectively, and estimated the seroprevalence. Although the statistical models are simpler under the accuracy assumption, the estimates can be biased unless the assumption is met as pointed out in Diggle (2011) . Under the inaccuracy assumption, Diggle (2011) proposed a corrected prevalence estimator and Silveira et al. (2020) constructed a confidence interval of the seroprevalence using a resampling method. In an analysis of a seroprevalence survey data of southern Brazil, Silveira et al. (2020) showed that confidence intervals can be {0}, which is hardly reliable. See Supplementary Table 2 in Silveira et al. (2020) . In Section 3, we also prove that the confidence interval constructed from the Rao's test using the duality theorem (Bickel and Doksum; 2015) can be the empty set. These examples show that the frequentist confidence intervals of the seroprevalence under the inaccuracy assumption can be unreliable.

In this paper, we propose a Bayesian method under the inaccuracy assumption and apply the proposed method to the seroprevalence surveys of the South Korean population conducted in 2020 (Korea Disease Control and Prevention Agency; 2021). We use the posterior distribution obtained from the Bayesian model of the clinical evaluation data (Kohmer et al.; as the informative prior distribution of the sensitivity and specificity on the diagnostic test.

The rest of the paper is organized as follows. In the next section, we describe the seroprevalence surveys of SARS-CoV-2 motivating this work and the plaque reduction neutralization test for detection of SARS-CoV-2 antibodies. In Section 3, we conduct a frequentist analysis and discuss the phenomenon of empty confidence sets. In Section 4, we propose a Bayesian method for the seroepidemiological survey that gives nonempty interval estimates, and analyze the seroprevalence surveys of the South Korean population using the proposed Bayesian method. We conclude the paper with a discussion section. Table 1 . In Table 1 , the periods during which the samples are collected are also given. 

When KDCA performed a serology test for SARS-CoV-2, KDCA used their in-house plaque reduction neutralization test (PRNT). In the PRNT, serum samples are tested for their neutralization capacity against SARS-CoV-2. To estimate the sensitivity and specificity of PRNT methods for SARS-CoV-2 empirically, we use a set of clinical evaluation data (Table 2) which is conducted by Kohmer et al. (2020) . 

Under the inaccuracy assumption, we specify a statistical model for seroprevalance surveys, and present the maximum likelihood estimator and a confidence interval of the seroprevalance. We assume that the sensitivity and specificity of serology test are fixed values for the estimator and the confidence interval. Note that the sensitivity and specificity are the probabilities that the positive has the positive test result and the negative has the negative test result, respectively.

We define seroprevalance parameter, θ, as the proportion of those who have antibodies against SARS-CoV-2 in the population. Let N be the number of samples of seroprevalence survey, X be the number of test-positive samples by serology test, and p + and p − denote the sensitivity and specificity of the serology test, respectively. We assume X is generated from the binomial distribution:

where Binom(n, p) denotes the binomial distribution with parameters n ∈ N and p ∈ [0, 1]. When p + and p − are known, the maximum likelihood estimator for θ is as follows.

and if p + < 1 − p − , then

Note if the number of test-positive samples is small or large enough, the maximum likelihood estimator can be 0 or 1. This means that nobody or everybody in the population has antibodies against SARS-CoV-2, which is hardly reliable.

We construct a confidence interval of θ from Rao's test (Rao; 1948) using the duality thoerem (Bickel and Doksum; 2015) , and show that when X is too small or large, the confidence interval can be the empty set. Let A(θ 0 ) = [l θ 0 , u θ 0 ] be the 100(1 − α)% acceptance interval of the Rao's test under the null hypothesis H 0 : θ = θ 0 . By the duality theorem S(X) = {θ 0 ∈ [0, 1] : X ∈ A(θ 0 )} is a 100(1 − α)% confidence interval for θ.

Theorem 3.1 gives the acceptance interval, A(θ 0 ), and the condition that the confidence interval S(X) is the empty set.

Theorem 3.1 Consider the model (1).

(a) The 100(1 − α)% acceptance region of the test

by the Rao's Score test is given as

The score statistics is

.

Then, 100(1 − α)% acceptance interval is

which proves (a).

It implies the confidence interval of X is the empty set.

This completes the proof.

The intuitive reason for the empty confidence interval is as follows. The set of sampling distributions for X is

When X/N is smaller (larger) than 1 − p − (p + ), the probability that X is observed is small for every sampling distribution in the set. This makes test decisions rejected for every null hypothesis. Thus, the extreme X implies p − and p + are doubtful.

For the three rounds of surveys given in Table 1 , we show all the maximum likelihood estimators are zero and the confidence intervals are the empty set. We assume the fixed (p + , p − ) to be (42/45, 34/35), which is calculated from the clinical evaluation data ( Table   2 ) and formula (r ++ /r ·+ , r −− /r ·− ) according to the notation in Table 3 . Based on equation (2) 

We propose a Bayesian method that avoids the empty confidence set problem. For the Bayesian analysis of model (1), we assign prior distributions on θ, p + and p − . According to KNHNES design, the parameter θ refers to the seroprevalence in the population that includes those who have been confirmed to be tested positive for COVID-19 by the government. Thus, it is reasonable to assume θ is larger than the proportion of the confirmed cases, and we choose the following constrained prior distribution on parameter θ:

where π(θ) is the density function of the prior distribution on θ, andθ is the total number of confirmed cases divided by the number of the population. Note that the constrained prior distribution (4) is constructed by constraining Jefferey's prior or reference prior distribution for binomial parameter (Yang and Berger; 1996) .

To construct prior distributions on p + and p − , we use the posterior distribution on the sensitivity and specificity obtained from a clinical evaluation of the serology test. In the clinical evaluation, we consider that the serology test is applied to samples of which the true states are known. The true state of a sample refers to whether the sample has the antibodies in reality. The data from the clinical evaluation is then represented as Table   3 . 

For the analysis of the clinical evaluation (Table 3) , we specify a statistical model using the binomial distribution as

By applying the Jefferey's prior (or reference prior) to the binomial parameters p + and p − , we obtain the densitiy functions of posterior distributions, π * (p + | r ++ , r ·+ ) and π * (p − | r −− , r ·− ), as

where p Binom (· | n, p) is the densitiy function of the binomial distribution Binom(n, p) for n ∈ N and p ∈ [0, 1]. Note that the Jefferey's prior is a conjugate prior for the likelihood function p Binom (· | n, p). Thus, the density function of the posterior distributions are calculated as

Finally, we use the posterior distributions to construct the informative prior distributions on p + , p − of model (1). That is, we set

where π(p + ) and π(p − ) are the densitiy functions of the informative prior distributions.

We analyze the survey data (Table 1) using the proposed Bayesian method. Let θ 1 , θ 2 and θ 3 be the seroprevalance parameters for each survey. We assign the constrained prior distributions on θ 1 , θ 2 and θ 3 as equation (4). When calculating the percentage of the confirmed cases, we use the cumulative confirmed cases at the last dates in the collection periods of the sets of samples, and let them denoted byθ 1 ,θ 2 andθ 3 . We construct informative prior distributions on p + and p − using the clinical evaluation of the PRNT for SARS-CoV-2 performed by Kohmer et al. (2020) . By applying the clinical evaluation data (Table 2) to equation (5), we obtain the informative prior distributions as p + ∼ Beta(42.5, 3.5)

where Beta(α, β) denotes the beta distribution with the density function of

Collecting the prior distributions and three rounds of seroprevalance survey results, we construct the generative model as Table 4 . According to Table 4 , the ratio of the posterior mean to the confirmed cases ranges from 3.1 to 4.5, which represents the proportion of (1). We use X/N as a point estimator for θ, and we construct a confidence interval of θ by Clopper and Pearson (1934) . As in the proposed Bayesian method, we multipy the number of the population to the point estimator and the confidence interval.

The comparison is then represented in Figure 1 . Figure 1 shows that the lower bounds of interval estimation by the Bayesian method are larger than the number of confirmed cases as expected, but the other does not satisfy the inequality condition. Each upper bound of the interval estimations by the Bayesian method is smaller than the corresponding one obtained under the accuracy assumption. Under the inaccuracy assumption, the Bayesian method considers that test-positive cases may include false-negative cases, which is critical when the test-positive number is small enough. Thus, the Bayesian method makes the upper bounds shrink.

In this article, we have proposed a Bayesian method with informative prior, which uses the clinical evaluation results of the plaque reduction neutralization test for analyzing data on the seroprevalence surveys in South Korea. We have compared the method with the frequentist's method under the inaccuracy assumption and the statistical analysis 

SeroTracker: a global SARS-CoV-2 seroprevalence dashboard

Mathematical statistics: basic ideas and selected topics

Stan: A probabilistic programming language

The use of confidence or fiducial limits illustrated in the case of the binomial

Estimating prevalence using an imperfect test

The species severe acute respiratory syndrome related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays

Data resource profile: The Korea National Health and Nutrition Examination Survey (KNHANES)

Demographics of Resident registration. URL: www.mois.go.kr

Seroprevalence of anti-SARS-CoV-2 antibodies among outpatients in southwestern Seoul

Large sample tests of statistical hypotheses concerning several parameters with applications to problems of estimation

Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil

IgG seroprevalence of COVID-19 among individuals without a history of the coronavirus disease infection in Daegu

Novel coronavirus (2019-nCoV): situation report

Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection

A catalog of noninformative priors, Institute of Statistics and Decision Sciences

A novel coronavirus from patients with pneumonia in China